# Foghorn Therapeutics Inc.: overview FHTX · Nasdaq · CIK 1822462 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fhtx.md) · [Financials](/companies/fhtx/financials.md) · [Filings](/companies/fhtx/filings.md) · [Insiders](/companies/fhtx/insiders.md) Latest reported revenue: [$16.1m](/filings/0001628280-26-053819.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053819). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.8](/filings/0001628280-25-049238.md) | [2.9 d](/filings/0001628280-26-016814.md) | [6.0](/filings/0001628280-26-031671.md) | [7.6](/filings/0001628280-26-053819.md) | [8.2](/filings/0001628280-25-049238.md) | [9.2 d](/filings/0001628280-26-016814.md) | [3.3](/filings/0001628280-26-031671.md) | [16.1](/filings/0001628280-26-053819.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(305.5%)](/filings/0001628280-25-049238.md) | [(840.5%) d](/filings/0001628280-26-016814.md) | [(385.0%)](/filings/0001628280-26-031671.md) | [(279.2%)](/filings/0001628280-26-053819.md) | [(226.9%)](/filings/0001628280-25-049238.md) | [(258.2%) d](/filings/0001628280-26-016814.md) | [(660.3%)](/filings/0001628280-26-031671.md) | [(54.8%)](/filings/0001628280-26-053819.md) | | Net margin | % | [(244.9%)](/filings/0001628280-25-049238.md) | [(682.9%) d](/filings/0001628280-26-016814.md) | [(316.4%)](/filings/0001628280-26-053819.md) | [(237.3%)](/filings/0001628280-26-053819.md) | [(194.4%)](/filings/0001628280-25-049238.md) | [(234.3%) d](/filings/0001628280-26-016814.md) | [(608.4%)](/filings/0001628280-26-053819.md) | [(44.7%)](/filings/0001628280-26-053819.md) | | Diluted EPS | $ per share | [(0.31)](/filings/0001628280-25-049238.md) | not reported | [(0.30)](/filings/0001628280-26-031671.md) | [(0.28)](/filings/0001628280-26-053819.md) | [(0.25)](/filings/0001628280-25-049238.md) | not reported | [(0.29)](/filings/0001628280-26-031671.md) | [(0.10)](/filings/0001628280-26-053819.md) | | Free cash flow | $m | [(21.3) d](/filings/0001628280-25-049238.md) | [(25.0) d](/filings/0001628280-26-016814.md) | [(24.0)](/filings/0001628280-26-031671.md) | [(21.0) d](/filings/0001628280-26-053819.md) | [(18.9) d](/filings/0001628280-25-049238.md) | [(22.3) d](/filings/0001628280-26-016814.md) | [(25.3)](/filings/0001628280-26-031671.md) | [(17.9) d](/filings/0001628280-26-053819.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.3](/filings/0001628280-23-007297.md) | [19.2](/filings/0001628280-24-009539.md) | [34.2](/filings/0001628280-25-010933.md) | [22.6](/filings/0001628280-26-016814.md) | [30.9](/filings/0001628280-26-016814.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7637.1%)](/filings/0001628280-23-007297.md) | [(609.2%)](/filings/0001628280-24-009539.md) | [(315.9%)](/filings/0001628280-25-010933.md) | [(454.3%)](/filings/0001628280-26-016814.md) | [(279.5%)](/filings/0001628280-26-016814.md) | | Net margin | % | [(7681.6%)](/filings/0001628280-23-007297.md) | [(566.3%)](/filings/0001628280-24-009539.md) | [(288.2%)](/filings/0001628280-25-010933.md) | [(383.2%)](/filings/0001628280-26-016814.md) | [(240.3%)](/filings/0001628280-26-016814.md) | | Diluted EPS | $ per share | [(2.73)](/filings/0001628280-23-007297.md) | [(2.62)](/filings/0001628280-24-009539.md) | [(2.34)](/filings/0001628280-25-010933.md) | [(1.58)](/filings/0001628280-26-016814.md) | [(1.18)](/filings/0001628280-26-016814.md) | | Free cash flow | $m | [(53.6)](/filings/0001628280-23-007297.md) | [192](/filings/0001628280-24-009539.md) | [(119)](/filings/0001628280-25-010933.md) | [(101)](/filings/0001628280-26-016814.md) | [(86.1)](/filings/0001628280-26-016814.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fhtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Flagship Pioneering, LLC](/funds/1400240.md) | 2026-06-30 | $61.8m | 12,674,120 | | Unchanged | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $28.5m | 5,842,000 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $27.8m | 5,705,958 | | Reduced −341,240 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $21.4m | 4,394,367 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.8m | 2,626,832 | | Added +261,966 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $12.2m | 2,489,978 | | Reduced −112,404 | | [Euclidean Capital LLC](/funds/1825034.md) | 2026-06-30 | $7.7m | 1,573,761 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.3m | 1,494,611 | | Reduced −478 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.4m | 910,866 | | Added +62,694 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $3.5m | 720,720 | | Unchanged | ## Recent filings [All 353 filings](/companies/fhtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 11:01 ET | [8-K](/filings/0001628280-26-064102.md) | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-064102 | | 2026-08-06 | 11:03 ET | [10-Q](/filings/0001628280-26-053819.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053819 | | 2026-08-06 | 11:01 ET | [8-K](/filings/0001628280-26-053817.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-053817 | | 2026-06-24 | 20:01 ET | [8-K](/filings/0001628280-26-045154.md) | 5.07 Shareholder vote results | 0001628280-26-045154 | | 2026-05-07 | 11:02 ET | [10-Q](/filings/0001628280-26-031671.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031671 | | 2026-05-07 | 11:01 ET | [8-K](/filings/0001628280-26-031669.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-031669 | | 2026-04-30 | 11:00 ET | [DEF 14A](/filings/0001193125-26-193928.md) | Proxy statement, period 2026-06-24 | 0001193125-26-193928 | | 2026-04-21 | 20:01 ET | [8-K](/filings/0001628280-26-026259.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-026259 | | 2026-03-11 | 20:11 ET | [10-K](/filings/0001628280-26-016814.md) | Annual report, period 2025-12-31 | 0001628280-26-016814 | | 2026-03-11 | 20:09 ET | [8-K](/filings/0001628280-26-016805.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-016805 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-016814.md), filed Mar 11, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bc58173e-c00e-4d1d-91ce-e8f3093b3f8c) ## About the filer - CIK: 1822462 - Tickers: FHTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.